1. Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia—A Retrospective Study in China 
Juan Tong, Li Xuan, Yanling Sun, Dongping Huang, Huilan Liu, Changcheng Zheng, Xiaoyu Zhu, Baolin Tang, Kaidi Song, Xuhan Zhang, Lei Zhang, Wen Yao, Dongjun Lin, Qifa Liu, Zimin Sun 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 9, Pages (September 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Among the patients who survived more than 100 days, the cumulative incidence of cGVHD at 3 years after transplantation in the UCBT group (20.4%; 95% CI, 9.79% to 29.8%) was lower than in the UPBSCT group (50.0%; 95% CI, 37.5% to 59.9%). (B) The cumulative incidence of moderate and severe cGVHD at 3 years after transplantation in the UCBT group (5.44%; 95% CI, .09% to 11.3%) was lower than in the UPBSCT group (28.62%; 95% CI, 15.5% to 39.7%).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) The incidence of CMV viremia was 76.2% (95% CI, 64.5% to 84.1%) in the UCBT group and 53.9% (95% CI, 42.7% to 63.0%) in the UPBSCT cohort. (B) The incidence of CMV disease was similar between the 2 groups (UCBT: 2.6%; 95% CI, 0 to 6.09% versus UPBSCT: 2.11%; 95% CI, 0 to 4.95%).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
(A) The cumulative incidence of EBV viremia at 3 years after transplantation in the UCBT group (3.01%; 95% CI, 0 to 7.09%) was lower than in the UPBSCT group (35.0%; 95% CI, 24.6% to 44.0%). (B) The cumulative incidence of PTLD at 3 years after transplantation in the UCBT group (1.72%; 95% CI, 0 to 5.02%) was lower than in the UPBSCT group (8.8%; 95% CI, 2.8% to 14.5%). (C) The 3-year GRFS for patients in the UCBT group was higher than in the UPBSCT group (54.4%; 95% CI, 42.8% to 64.6% versus 39.4%; 95% CI, 29.6% to 49.0%).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions